Description
Aromasin belongs to a category and class of drugs known as aromatase inhibitors (AIs). Aromatase inhibitors are part of a broader class of drugs called anti-estrogens. The other subcategory under the anti-estrogens classification is selective estrogen receptor modulators (SERMs), such as Nolvadex and Clomid. Together, AIs and SERMs make up the anti-estrogen family. However, aromatase inhibitors differ significantly from SERMs in their mechanism of action and how they address estrogen control.
For years, a widespread misunderstanding has persisted within the anabolic steroid and bodybuilding communities, though clarity has improved over the last 10–15 years. This misconception revolves around the belief that SERMs, such as Nolvadex and Clomid, lower estrogen levels. This myth likely stems from the fact that SERMs are often referred to as “estrogen blockers,” leading some to mistakenly interpret “blocking estrogen” as “eliminating estrogen,” which is entirely inaccurate. SERMs do not reduce circulating estrogen levels in the bloodstream. Instead, they block estrogen activity in specific tissues by occupying estrogen receptor sites, particularly in breast tissue, preventing estrogen from exerting its effects there. Additionally, SERMs can act as estrogen agonists in other tissues, such as the liver in the case of Nolvadex. This selective action is where the term “selective estrogen receptor modulator” originates. However, SERMs do not lower overall estrogen levels in the body. That role falls to aromatase inhibitors, which work by binding to and disabling the aromatase enzyme, the enzyme responsible for converting androgens into estrogen.
Aromasin is a highly potent steroidal aromatase inhibitor of the suicidal type. Prescription Aromasin packaging includes information indicating its ability to reduce estrogen levels by up to 85%, as demonstrated in studies involving breast cancer patients[1]. Suicidal aromatase inhibitors like Aromasin (Exemestane) permanently inhibit and disable the aromatase enzyme they bind to[2]. Once bound, the enzyme is rendered inactive indefinitely. While the body will eventually produce new aromatase enzymes, the bound enzymes remain permanently disabled, eliminating the risk of estrogen rebound. This is a key distinction from non-suicidal aromatase inhibitors like Arimidex and Letrozole, which only temporarily bind to the aromatase enzyme. If non-suicidal inhibitors are discontinued abruptly, the inhibited enzymes can become active again, leading to a rapid resurgence of estrogen production. This risk does not exist with Aromasin.
For high-quality Aromasin and other performance-enhancing products, trust Rx Anabolics. We are committed to providing premium products and reliable information to support your goals.
Reviews
There are no reviews yet.